drug · small molecule
VTx-002
Phase 2updated 6mo agoby VectorY Therapeutics Inc🔗 ChEMBL
Phase 2community read0 votes
Small molecule drug with a maximum clinical stage of Phase 2 (across all indications), with 2 investigational indications.
indications
indications
ALS
all catalysts(0)
nothing on the calendar yet
Trials studying VTx-002
News(1)
- VectorY bags $83.5M for antibody gene therapies in neurodegenerative diseasesVectorY Therapeutics added €74.5 million ($83.5 million) to its Series A to fund a gene therapy that makes antibodies in the brain. The biotech’s lead asset VTx-002 is in aendpoints · 8d ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that